Skip to main content

Tweets

The EMA CHMP has started a review of oral complement C5 inhibitor avacopan (Tavneos) based on serious questions about amendments to the data from the pivotal ADVOCATE study. The drug was approved in 2021 for use in GPA & MPA. https://t.co/a5ggUqk1dG

Dr. John Cush @RheumNow ( View Tweet )

1 month ago
TOPKAT Trial: Partial vs Total Knee Replacement Patients with osteoarthritis (OA) primarily affecting only one knee joint compartment did just as well with partial knee replacement (PKR) as with total arthroplasty after 10 years in a randomized trial -- and maybe a little bit https://t.co/MNpVeHQbJ2
Dr. John Cush @RheumNow ( View Tweet )
1 month ago
DMARD Responses in Localized Scleroderma JAMA Dermatology has published the results of a juvenile localized scleroderma (JLS) trial showing that mycophenolate mofetil (MMF) and methotrexate (MTX) are equally effective in treating JLS, noting low flare rates and possibly better https://t.co/BbIS5rdRYU
Dr. John Cush @RheumNow ( View Tweet )
1 month ago
“Play the game for more than you can afford to lose... only then will you learn the game.” - Winston Churchill

Dr. John Cush @RheumNow ( View Tweet )

1 month ago
Full read review of the Mechanistic Effects of Methotrexate in the Treatment of Rheumatoid Arthritis. https://t.co/PrMyZ7q3wX download here: https://t.co/aRnmRm770Z https://t.co/5B0mBjzOXQ
Dr. John Cush @RheumNow ( View Tweet )
1 month ago
B Cells at the Brink in Sjögren Disease The current issue of Arthritis & Rheumatology reviews the current understanding of the immunopathogenesis of Sjögren disease (SjD) and how this understanding has informed drug development for this systemic autoimmune disorder. https://t.co/p3dn1Ca2ag
Dr. John Cush @RheumNow ( View Tweet )
1 month ago
Clinical contributors to pathogenesis and treatment outcomes for rheumatoid arthritis. Full read review of pathogenesis and unmet needs in #RA https://t.co/IEC0tsp1Rk https://t.co/jIsqhy9rQh
Dr. John Cush @RheumNow ( View Tweet )
1 month ago
Roche Canada announced that Health Canada has approved obinutuzumab (Gazyva) for the treatment of adult patients with active lupus nephritis who are receiving standard therapy. Following four initial doses in the first year, Gazyva can be administered twice yearly https://t.co/P4dCVkoPCH
Dr. John Cush @RheumNow ( View Tweet )
1 month ago
Testing for RF, CCP, ESR and CRP Check out the accompanying Advanced Practice Rheum: Rheumatoid and Inflammation Testing video. https://t.co/4hkDO1M2UD https://t.co/APRKYLAS3k
Dr. John Cush @RheumNow ( View Tweet )
1 month ago
APPIPRA Study - Benefits of Early Treatment Treating people who are at high risk of rheumatoid arthritis (RA) can delay the onset of the disease for several years, with benefits also continuing well after treatment has stopped. https://t.co/GYguq7VlqT https://t.co/5Z0BXIm3cM
Dr. John Cush @RheumNow ( View Tweet )
1 month ago
NEJM - Baker’s Cyst A 63-year-old woman with psoriatic arthritis presented with a 9-month history of pain in the left knee. A nontender, palpable mass was present in the left popliteal fossa, which had a “speech bubble” shape on ultrasonography. https://t.co/7wBnkDoUaX https://t.co/m0AhRnDc4c
Dr. John Cush @RheumNow ( View Tweet )
1 month ago
Expertise is valued by all, YET, (many consider) change might be risky. (happened w/ Hand-washing, antibiotics, smoking dangers, etc). "Just because the establishment doesn’t like it doesn’t mean it’s not a good idea. " - Seth Godin https://t.co/3vQ4eHa4jr https://t.co/9mIJwD1f7z
Dr. John Cush @RheumNow ( View Tweet )
1 month ago
×